Undisclosed Oncology Programs

About General Proximity

General Proximity is an early-stage biotech leveraging a proprietary proximity discovery engine, OmniTAC™, to create novel therapeutics that modulate protein function by controlling intracellular proximity events. The company has secured backing from leading technical investors and major grants, and has established a multi-target collaboration with Daiichi Sankyo in oncology. With a seasoned team from top academic and industry institutions, General Proximity is positioned to advance a pipeline of proximity medicines, though it remains pre-clinical and pre-revenue.

About TRIANA Biomedicines

TRIANA Biomedicines is a private, preclinical-stage biotech pioneering a rational, target-first platform for molecular glue discovery, initially targeting oncology. The company's technology seeks to systematically identify small molecules that 'glue' disease-causing proteins to components of the cell's ubiquitin-proteasome system, leading to their degradation. Led by an experienced team with a track record in drug discovery and development, TRIANA is tackling undruggable targets in cancer. The company is venture-backed and positioned in the high-potential but competitive field of targeted protein degradation.

About Sprint Bioscience

Sprint Bioscience is a preclinical-stage biotech company leveraging fragment-based drug discovery to develop novel oncology therapeutics. Its capital-efficient business model centers on advancing programs to a preclinical proof-of-concept before out-licensing them to larger pharma partners, as demonstrated by a major deal with Gilead Sciences. The company is expanding its pipeline into metabolic/inflammatory diseases through collaborations, aiming to address high-need areas with significant commercial potential.

About BridGene Biosciences

BridGene Biosciences is an early-stage, platform-focused biotech leveraging its innovative IMTAC™ chemoproteomics technology to tackle undruggable disease targets. The company's approach allows for the systematic screening of small molecules against the entire proteome, identifying novel binding sites and chemical starting points for drug development. Its initial pipeline is concentrated in oncology, with programs targeting transcription factors and other difficult proteins. As a private company, BridGene's success hinges on validating its platform through internal pipeline advancement and strategic partnerships.

About Albega Medical

Albega Medical GmbH is a private, preclinical-stage biotech company pioneering targeted radiopharmaceuticals for cancer theranostics. Operating from Berlin, the company is building a pipeline of novel radio-ligands designed to diagnose and treat tumors with high precision. As a pre-revenue entity, it is likely reliant on venture funding or partnerships to advance its research. The company's success hinges on translating its preclinical candidates into clinical proof-of-concept within the competitive and technically complex radiopharma sector.

Therapeutic Areas

Other Oncology Drugs